PDF(Pubmed)
Abstract：
UNASSIGNED: Strategies therapy for hepatocellular carcinoma (HCC) beyond oligometastasis are limited. The optimal sequence of systemic treatment for advanced HCC is not yet clear. Our study aims to evaluate the effectiveness of simultaneous lenvatinib combined PD-1 inhibitor on advanced HCC beyond oligometastasis.
UNASSIGNED: A total of 232 patients were enrolled in our retrospective study. Patients divided into three groups. (a) Lenvatinib plus simultaneous PD-1 inhibitor (Simultaneous group, n=58); (b) patients received PD-1 inhibitor before the tumor progression with continued lenvatinib administration (Before PD group, n=77); (c) patients received PD-1 inhibitor after the tumor progression (After PD group, n=97). To analyze overall survival (OS) and progression-free survival (PFS) among the three groups.
UNASSIGNED: The estimated 6-, 12-, 18- and 24-mon OS for Simultaneous group patients were 100%, 93.1%, 63.4%, 48.3%, whereas the OS rates were 100%, 78%, 36.3%, 23.6% in Before PD group, and 99%, 61.2%, 22.1%, 7.5% in After PD group. The OS rates were obviously improved with the use of simultaneous PD-1 inhibitor among the three groups (P <0.001). The estimated 3-, 6-, 9- and 12-month PFS rates for patients were 89.6%, 44.8%, 24.6%, 6% in After PD group, 90.9%, 59.7%, 27.3%, 12.4% in Before PD group and 98.3%, 81%, 51.7%, 39.7% in Simultaneous group, respectively. PFS rate was significantly different among the three groups (P <0.001).
UNASSIGNED: Synchronous administration of lenvatinib and PD-1 inhibitors improved survival rate significantly. The synchronous combination could represent a promising strategy in HCC beyond oligometastasis.
UNASSIGNED: A total of 232 patients were enrolled in our retrospective study. Patients divided into three groups. (a) Lenvatinib plus simultaneous PD-1 inhibitor (Simultaneous group, n=58); (b) patients received PD-1 inhibitor before the tumor progression with continued lenvatinib administration (Before PD group, n=77); (c) patients received PD-1 inhibitor after the tumor progression (After PD group, n=97). To analyze overall survival (OS) and progression-free survival (PFS) among the three groups.
UNASSIGNED: The estimated 6-, 12-, 18- and 24-mon OS for Simultaneous group patients were 100%, 93.1%, 63.4%, 48.3%, whereas the OS rates were 100%, 78%, 36.3%, 23.6% in Before PD group, and 99%, 61.2%, 22.1%, 7.5% in After PD group. The OS rates were obviously improved with the use of simultaneous PD-1 inhibitor among the three groups (P <0.001). The estimated 3-, 6-, 9- and 12-month PFS rates for patients were 89.6%, 44.8%, 24.6%, 6% in After PD group, 90.9%, 59.7%, 27.3%, 12.4% in Before PD group and 98.3%, 81%, 51.7%, 39.7% in Simultaneous group, respectively. PFS rate was significantly different among the three groups (P <0.001).
UNASSIGNED: Synchronous administration of lenvatinib and PD-1 inhibitors improved survival rate significantly. The synchronous combination could represent a promising strategy in HCC beyond oligometastasis.
摘要：
■对寡转移以外的肝细胞癌（HCC）的策略治疗是有限的。晚期HCC的全身治疗的最佳顺序尚不清楚。我们的研究旨在评估乐伐替尼联合PD-1抑制剂对晚期HCC的疗效。
■我们的回顾性研究共纳入了232例患者。患者分为三组。（a）Lenvatinib加同时PD-1抑制剂（同时组，n=58）；（b）患者在肿瘤进展前接受PD-1抑制剂，并继续lenvatinib给药（PD组之前，n=77)；(c)患者在肿瘤进展后接受PD-1抑制剂(PD组，n=97）。分析3组患者的总生存期(OS)和无进展生存期(PFS)。
■估计的6-，12-，同期组患者的18-和24-monOS为100%，93.1%,63.4%,48.3%,而OS率为100%，78%,36.3%,PD组之前的23.6%，99%,61.2%,22.1%,术后PD组为7.5%。3组同时使用PD-1抑制剂后，OS率均明显提高（P<0.001）。估计的3,6-，患者9个月和12个月的PFS率为89.6%，44.8%,24.6%,6％在后PD组，90.9%,59.7%,27.3%,PD前组12.4%,98.3%,81%,51.7%,同时组39.7%，分别。三组间PFS差异有统计学意义(P<0.001)。
■乐伐替尼和PD-1抑制剂的同步给药显著提高了生存率。同步组合可以代表肝癌中超越寡转移的有希望的策略。
■我们的回顾性研究共纳入了232例患者。患者分为三组。（a）Lenvatinib加同时PD-1抑制剂（同时组，n=58）；（b）患者在肿瘤进展前接受PD-1抑制剂，并继续lenvatinib给药（PD组之前，n=77)；(c)患者在肿瘤进展后接受PD-1抑制剂(PD组，n=97）。分析3组患者的总生存期(OS)和无进展生存期(PFS)。
■估计的6-，12-，同期组患者的18-和24-monOS为100%，93.1%,63.4%,48.3%,而OS率为100%，78%,36.3%,PD组之前的23.6%，99%,61.2%,22.1%,术后PD组为7.5%。3组同时使用PD-1抑制剂后，OS率均明显提高（P<0.001）。估计的3,6-，患者9个月和12个月的PFS率为89.6%，44.8%,24.6%,6％在后PD组，90.9%,59.7%,27.3%,PD前组12.4%,98.3%,81%,51.7%,同时组39.7%，分别。三组间PFS差异有统计学意义(P<0.001)。
■乐伐替尼和PD-1抑制剂的同步给药显著提高了生存率。同步组合可以代表肝癌中超越寡转移的有希望的策略。
